Lysophosphatidylcholine 18:2-d9(Synonyms: 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC-d9)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Lysophosphatidylcholine 18:2-d9 (Synonyms: 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC-d9)

Lysophosphatidylcholine 18:2-d9 是 Lysophosphatidylcholine 18:2 的氘代物。Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC)，一种溶血磷脂，是一种从胰岛素抵抗 (IR) 多囊卵巢综合征 (PCOS) 中发现的潜在生物标志物。低血浆 Lysophosphatidylcholine 18:2 还可以预测糖耐量受损、胰岛素抵抗、2 型糖尿病、冠心病和记忆障碍。

Lysophosphatidylcholine 18:2-d9(Synonyms: 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC-d9)

Lysophosphatidylcholine 18:2-d9 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Lysophosphatidylcholine 18:2-d9 is deuterium labeled Lysophosphatidylcholine 18:2. Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

528.71

Formula

C26H41D9NO7P
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Gonzalez-Freire M, et al. Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci. 2019;74(1):62-67.

    [2]. Chen YX, et al. UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance. J Pharm Biomed Anal. 2016;121:141-150.

    [3]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务